找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nanomedicines for Effective Cancer Therapy; Hitoshi Kasai,Hiroshi Uji-i,Johan Hofkens Book 2024 The Editor(s) (if applicable) and The Auth

[復(fù)制鏈接]
樓主: Forestall
31#
發(fā)表于 2025-3-26 23:09:01 | 只看該作者
Targeted Drug Delivery for Cancer Therapy Using Functionalized Nanocarrierse therapies are based on passive accumulation in tumor tissues via enhanced permeability of tumor vasculature, namely the enhanced permeability and retention effect (EPR effect). However, the efficacy of EPR-based drug delivery is controversial because liposomal doxorubicin potentially has an insuf
32#
發(fā)表于 2025-3-27 02:24:08 | 只看該作者
Cancer Photo Therapies that Target Mitochondriapeutic molecule of choice to act where it is needed and for the required time. Cancer photo therapy typically involves photochemical reactions induced by light irradiation to cause cell death. Over the past few decades, mitochondria have attracted considerable attention in the field of therapy. The
33#
發(fā)表于 2025-3-27 05:54:26 | 只看該作者
34#
發(fā)表于 2025-3-27 12:23:45 | 只看該作者
35#
發(fā)表于 2025-3-27 13:43:27 | 只看該作者
36#
發(fā)表于 2025-3-27 19:25:00 | 只看該作者
Cell Membrane Mimetic Amphiphilic Phospholipid Polymers for Advanced Nanomedicinee, we introduce phospholipid polymers, whose molecular design is based on the surface structure of cell membranes, and their role in drug formulation. These phospholipid polymers are amphiphilic, can substantially enhance the solubility of drugs in aqueous media, and can permeate membranes through m
37#
發(fā)表于 2025-3-27 23:17:52 | 只看該作者
38#
發(fā)表于 2025-3-28 04:45:33 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:50 | 只看該作者
3D Tumor Models—Nanomedicine in the Third Dimensionnced efficacy and reduced side effects has marked a significant step forward in cancer research. However, the promising results observed in preclinical studies show low translatability into the clinic, due to a lack of adequate preclinical models that faithfully mimic the complex tumor microenvironm
40#
發(fā)表于 2025-3-28 11:55:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 14:26
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
招远市| 绥中县| 开平市| 同仁县| 鄯善县| 连南| 龙井市| 蒙阴县| 葵青区| 鸡泽县| 淄博市| 宜黄县| 永年县| 甘孜县| 抚松县| 彭山县| 六枝特区| 仁布县| 海门市| 登封市| 石楼县| 榆林市| 乌拉特中旗| 理塘县| 民丰县| 建始县| 江华| 遂川县| 都安| 四平市| 甘孜县| 亚东县| 和龙市| 项城市| 汤原县| 贵德县| 沛县| 西华县| 临沭县| 宁津县| 建始县|